Analgesic medicine sales in Canada are projected to decline gradually from 2024 to 2028, with values decreasing from $808.5 million to $785.1 million USD PPP. In 2023, the market stood at approximately $814 million. This represents a year-on-year decrease of around 0.8% in 2024 and continues to decline annually. The CAGR for the period from 2023 to 2028 is negative, indicating a consistent reduction in projected sales over these years.

Future trends to watch for include:

Changes in consumer preferences towards non-pharmaceutical pain relief options.
Potential regulatory changes impacting the availability or pricing of analgesic medicines.
Advancements or innovations in analgesic formulations that could shift market dynamics.